查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363063

抗病毒药物市场规模、份额和趋势分析报告：按类型、药物类别、配销通路、用途、区域、细分趋势，2023-2030

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

抗病毒药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球抗病毒药物市场规模将达到620.5亿美元，2023年至2030年年复合成长率为-1.99%。

这是由病毒性疾病患病上升以及政府不断增加的与开发新疗法以减少感染疾病传播相关的倡议所推动的。此外，加强研发力度以及扩大免疫和联合治疗等最新细节预计将推动市场成长。病毒大流行的可能性凸显了对广谱抗病毒药物的需求，例如直接作用的抗病毒药物，可以立即大规模部署，以阻止病毒的传播，直到有足够的疫苗接种为止。抗病毒重磅疗法的出现彻底改变了各种病毒感染疾病的治疗方法。

值得注意的例子包括在丙型肝炎治疗中引入直接作用抗病毒药物（DAA），例如Sovaldi（索磷布韦）、Harvoni（雷迪帕韦/索磷布韦）和Epclosa（索磷布韦/维帕他韦），它透过实现更高的治癒率彻底改变了这一领域与以前相比，治疗速度更快、治疗时间更短、副作用更少。这些药物已获得重磅炸弹地位，因为它们可以有效治癒丙型肝炎并解决未满足的医疗需求。政府对抗病毒药物的配合措施包括资助研究和开发、简化核准和紧急使用授权的法规流程、战略储备以备不时之需，以及加快开发有效的抗病毒治疗方法，其中包括与行业和学术机构合作以提高可用性。

例如，2022年5月，美国国立卫生研究院下属的国家过敏和感染疾病研究所（NIAID）针对大流行病病原体建立了9个抗病毒药物发现（AViDD）中心，并提供了约5.77亿美元提高经济成长水准。此外，政府机构和主要企业之间合作的加强预计将推动新型抗病毒药物研发活动的成长。例如，2021 年 6 月，默克公司与美国政府签订了 molnupiravir 的采购协议，molnupiravir 是一种用于治疗 COVID-19 的在临床实验抗病毒药物。根据协议，如果molnupiravir获得美国FDA紧急使用核准或核准，该公司将获得12亿美元并向美国政府供应约170万疗程的药物。

此外，市场参与者正在采取策略性配合措施来满足临床测试日益增长的需求。大公司正在收购地区性公司以加强其市场地位。正因为如此，这个地区的玩家之间的竞争非常激烈。市场参与者正专注于开发新产品。例如，截至 2023 年 6 月，有超过 900 项研究正在进行抗病毒药物开发的 2 期、3 期和 4 期临床试验。此外，PharmaMar将于2023年4月开始Nereida临床试验，使用罹患治疗COVID-19的免疫抑制患者，该试验将在西班牙、义大利、法国、波兰、匈牙利、希腊和葡萄牙使用，该试验已获得核准。

抗病毒药物市场报告亮点

  • 该品牌类型因其经过验证的功效、安全性以及核准而广泛采用，在 2022 年占据市场主导地位。
  • 按药物类别划分，由于爱滋病毒/爱滋病等慢性疾病的流行增加了对有效治疗药物的需求，蛋白酶抑制剂细分市场将在 2022 年占据主导地位。
  • 从配销通路来看，由于患病人数不断增加、高龄化以及住院患者数量不断增加，医院药房板块在2022年将占据最大的市场占有率。
  • 由于拥有完善的医疗基础设施、病毒性疾病的高患病以及治疗药物的快速发展，北美已在市场上确立了区域地位。

目录

第1章调查方法和范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场趋势及展望
  • 市场动态
    • 病毒感染疾病的传播
    • 加强政府应对病毒感染疾病的配合措施
    • 老年人口增加
  • 市场抑制因素分析
    • 昂贵的治疗费用
  • 营商环境分析
    • SWOT 分析；要素因素（政治/法律、经济/技术）
    • 波特五力分析
  • COVID-19感染疾病的影响分析

第4章按类型分類的业务分析

  • 抗病毒药物市场：类型变异分析
  • 品牌
  • 通用的

第5章医药类业务分析

  • 抗病毒药物市场：药品类别波动分析
  • DNA聚合酶抑制剂
  • 逆转录酶抑制剂
  • 蛋白酶抑制剂
  • 神经氨酸酶抑制剂
  • 其他的

第6章配销通路业务分析

  • 抗病毒药物市场：配销通路波动分析
  • 医院药房
  • 零售药房
  • 网路药房

第7章用途业务分析

  • 抗病毒药物市场：应用变化分析
  • 流感
  • HIV
  • 肝炎
  • 疱疹
  • 其他的

第8章区域业务分析

  • 2022年及2030年抗病毒药物市场占有率（按地区）
  • 北美洲
    • SWOT分析
    • 2018-2030年北美抗病毒药物市场
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 欧洲抗病毒药物市场，2018-2030
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 2018-2030年亚太地区抗病毒药物市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲抗病毒药物市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • SWOT分析
    • MEA抗病毒药物市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022年主要企业市场占有率分析
  • 企业热力图分析
  • 公司简介
    • F. HOFFMANN-LA ROCHE LTD.
    • GSK PLC.
    • ABBVIE, INC.
    • MERCK &CO., INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • CIPLA INC.
    • AUROBINDO PHARMA
    • DR. REDDY'S LABORATORIES LTD.
Product Code: GVR-1-68038-389-8

Antiviral Drugs Market Growth & Trends:

The global antiviral drugs market size is expected to reach USD 62.05 billion by 2030, registering a CAGR of -1.99% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This is attributed to the rising prevalence of viral diseases and growing government initiatives pertaining to the development of novel therapeutics to reduce the spread of infections. Furthermore, an increase in R&D efforts and the expansion of more recent & updated details, such as vaccinations and combined therapy, are projected to propel the growth of the market. Potential viral pandemics highlight the need for broad-spectrum antiviral drugs, such as direct-acting antivirals, that can be immediately deployed on a massive scale to halt viral spread until suitable vaccinations are created. Introducing blockbuster therapeutics for antiviral drugs has been transformative in treating various viral infections.

These drugs have demonstrated significant efficacy, widespread use, and substantial revenue generation for pharmaceutical companies.One prominent example is the introduction of Direct-acting Antivirals (DAAs) for the treatment of hepatitis C drugs, such as Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (sofosbuvir/velpatasvir), revolutionized the field by providing high cure rates, shorter treatment durations, and fewer side effects compared to previous therapies. These drugs achieved blockbuster status due to their effectiveness in curing hepatitis C and addressing a significant unmet medical need. Government initiatives for antiviral drugs include funding for R&D, streamlining regulatory processes for approval and emergency use authorizations, strategic stockpiling for preparedness, and collaborations with industry & academic institutions to accelerate development and ensure accessibility of effective antiviral treatments.

For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, granted around USD 577 million to launch nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Moreover, increasing collaborations between government bodies and key players are anticipated to fuel the growth of R&D activities for developing novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million drug courses to the U.S. government if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Furthermore, market entities are undertaking strategic initiatives to address the growing demand for clinical tests. Major players are involved in the acquisition of regional players to strengthen their position in the market. Thus, there is significant competition among players in this region. Players in the market are focusing on developing new products. For instance, as of June 2023, over 900 studies are ongoing in phases 2, 3, and 4 of clinical trials for antiviral drug development. Moreover, in April 2023, PharmaMar initiated the Nereida clinical trial using plitidepsin for the treatment of immunosuppressed patients suffering from COVID-19, with trials being approved in Spain, Italy, France, Poland, Hungary, Greece, and Portugal.

Antiviral Drugs Market Report Highlights:

  • The branded type segment dominated the market in 2022 as they are widely adopted due to their proven efficacy, safety profile, and endorsement by healthcare authorities
  • On the basis of drug class, the protease inhibitors segmentdominated the market in 2022 owing to the rising need for effective therapeutics due to the increasing prevalence of chronic diseases, such as HIV/AIDS
  • Based on distribution channel, the hospital pharmacy segment held the largest market share in 2022owing to an increasing number of people suffering from diseases, a rapidly aging population, and a growing number of hospitalizations
  • North America has established a strong regional position in the market due to the presence of well-established healthcare infrastructure,a high prevalence of viral diseases, and rapid advancements in therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing prevalence of viral infections
    • 3.4.2. Increasing government initiatives for viral infections
    • 3.4.3. Increasing geriatric population
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Antiviral Drugs Market: Type Movement Analysis
  • 4.2. Branded
    • 4.2.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.3. Generics
    • 4.3.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Antiviral Drugs Market: Drug Class Movement Analysis
  • 5.2. DNA Polymerase Inhibitors
    • 5.2.1. DNA Polymerase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.3. Reverse Transcriptase Inhibitors
    • 5.3.1. Reverse Transcriptase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.4. Protease Inhibitors
    • 5.4.1. Protease Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Neuraminidase Inhibitors
    • 5.5.1. Neuraminidase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Antiviral Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Antiviral Drugs Market: Application Movement Analysis
  • 7.2. Influenza
    • 7.2.1. Influenza Market, 2018 - 2030 (USD Million)
  • 7.3. HIV
    • 7.3.1. HIV Market, 2018 - 2030 (USD Million)
  • 7.4. Hepatitis
    • 7.4.1. Hepatitis Market, 2018 - 2030 (USD Million)
  • 7.5. Herpes
    • 7.5.1. Herpes Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antiviral Drugs Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. U.S. Antiviral drugs Market, 2018 - 2030 (USD MILLION)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.4. UK
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. France Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Reimbursement Scenario
      • 8.3.10.6. Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. China Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. India Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Reimbursement Scenario
      • 8.4.8.6. Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Reimbursement Scenario
      • 8.5.5.6. Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Reimbursement Scenario
      • 8.6.6.6. Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Product Launch
    • 9.2.2. Partnership
    • 9.2.3. Acquisition
    • 9.2.4. Collabboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2022
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. F. HOFFMANN-LA ROCHE LTD.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GSK PLC.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. ABBVIE, INC.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. MERCK & CO., INC.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. JOHNSON & JOHNSON SERVICES, INC.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BRISTOL-MYERS SQUIBB COMPANY
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. CIPLA INC.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AUROBINDO PHARMA
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. DR. REDDY'S LABORATORIES LTD.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 Global Antiviral Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Canada Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 Europe Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Europe Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Germany Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 UK Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 UK Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 UK Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 UK Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 33 France Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 France Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 35 France Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 Italy Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Italy Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Italy Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 Spain Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Spain Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Denmark Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Denmark Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 49 Sweden Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Sweden Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 Norway Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Norway Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 China Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 63 China Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 China Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 China Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 66 Japan Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Japan Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Japan Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Japan Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 70 India Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 India Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 India Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 India Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 74 South Korea Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 76 South Korea Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 South Korea Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 78 Australia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 80 Australia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Australia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 82 Thailand Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Thailand Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Thailand Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Latin America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 91 Brazil Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 93 Brazil Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Brazil Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 95 Mexico Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 97 Mexico Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Mexico Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 99 Argentina Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 101 Argentina Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 102 Argentina Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 109 South Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 115 UAE Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 117 UAE Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Antiviral Drugs Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Antiviral Drugs Market: Type Movement Analysis
  • Fig. 17 Global Antiviral Drugs Market, by Branded, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antiviral Drugs Market, by Generics, 2018 - 2030 (USD Million)
  • Fig. 19 Global Antiviral Drugs Market: Drug Class Movement Analysis
  • Fig. 20 Global Antiviral Drugs Market, by DNA Polymerase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 21 Global Antiviral Drugs Market, by Reverse Transcriptase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 22 Global Antiviral Drugs Market, by Protease Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 23 Global Antiviral Drugs Market, by Neuraminidase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 24 Global Antiviral Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Global Antiviral Drugs Market: Distribution Channel Movement Analysis
  • Fig. 26 Global Antiviral Drugs Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 27 Global Antiviral Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global Antiviral Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2022 & 2030
  • Fig. 31 Global Antiviral Drugs Market: Region Movement Analysis
  • Fig. 32 North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)